|
1
|
Xiong Y, Sun F, Dong P, Watari H, Yue J,
Yu MF, Lan CY, Wang Y and Ma ZB: iASPP induces EMT and cisplatin
resistance in human cervical cancer through miR-20a-FBXL5/BTG3
signaling. J Exp Clin Cancer Res. 36:482017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li M, Feng YM and Fang SQ: Overexpression
of ezrin and galectin-3 as predictors of poor prognosis of cervical
cancer. Braz J Med Biol Res. 50:e53562017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang M, Zhang H, Yu Y, Huang H, Li G and
Xu C: Synergistic effects of a novel lipid-soluble extract from
Pinellia pedatisecta Schott and cisplatin on human cervical
carcinoma cell lines through the regulation of DNA damage response
signaling pathway. Oncol Lett. 13:2121–2128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang L, Huang Z, Fan Y, He L, Ye M, Shi
K, Ji B, Huang J, Wang Y and Li Q: FOXC1 promotes proliferation and
epithelial-mesenchymal transition in cervical carcinoma through the
PI3K-AKT signal pathway. Am J Transl Res. 9:1297–1306.
2017.PubMed/NCBI
|
|
5
|
Pedroza-Torres A, López-Urrutia E,
García-Castillo V, Jacobo-Herrera N, Herrera LA, Peralta-Zaragoza
O, López-Camarillo C, De Leon DC, Fernández-Retana J, Cerna-Cortés
JF and Pérez-Plasencia C: MicroRNAs in cervical cancer: Evidences
for a miRNA profile deregulated by HPV and its impact on
radio-resistance. Molecules. 19:6263–6281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tang T, Wong HK, Gu W, Yu MY, To KF, Wang
CC, Wong YF, Cheung TH, Chung TK and Choy KW: MicroRNA-182 plays an
onco-miRNA role in cervical cancer. Gynecol Oncol. 129:199–208.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen B, Hou Z, Li C and Tong Y: MiRNA-494
inhibits metastasis of cervical cancer through Pttg1. Tumour Biol.
36:7143–7149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cavalleri T, Angelici L, Favero C, Dioni
L, Mensi C, Bareggi C, Palleschi A, Rimessi A, Consonni D, Bordini
L, et al: Plasmatic extracellular vesicle microRNAs in malignant
pleural mesothelioma and asbestos-exposed subjects suggest a
2-miRNA signature as potential biomarker of disease. PLoS One.
12:e01766802017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cho WC: MicroRNAs: Potential biomarkers
for cancer diagnosis, prognosis and targets for therapy. Int J
Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lam CS, Ng L, Chow AK, Wan TM, Yau S,
Cheng NS, Wong SK, Man JH, Lo OS, Foo DC, et al: Identification of
microRNA 885-5p as a novel regulator of tumor metastasis by
targeting CPEB2 in colorectal cancer. Oncotarget. 8:26858–26870.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu Z, Zhou Y, Shi F, Cao Y, Dinh TLA, Wan
J and Zhao M: Investigation of differentially-expressed microRNAs
and genes in cervical cancer using an integrated bioinformatics
analysis. Oncol Lett. 13:2784–2790. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang W, Li Y, Liu N, Gao Y and Li L:
MiR-23b controls ALDH1A1 expression in cervical cancer stem cells.
BMC Cancer. 17:2922017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harafuji N, Schneiderat P, Walter MC and
Chen YW: miR-411 is up-regulated in FSHD myoblasts and suppresses
myogenic factors. Orphanet J Rare Dis. 8:552013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi X, Xiao X, Yuan N, Zhang S, Yuan F and
Wang X: MicroRNA-379 suppresses cervical cancer cell proliferation
and invasion by directly targeting V-crk avian sarcoma virus CT10
oncogene homolog-like (CRKL). Oncol Res. 26:987–996. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun M, Huang F, Yu D, Zhang Y, Xu H, Zhang
L, Li L, Dong L, Guo L and Wang S: Autoregulatory loop between
TGF-β1/miR-411-5p/SPRY4 and MAPK pathway in rhabdomyosarcoma
modulates proliferation and differentiation. Cell Death Dis.
6:e18592015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xia K, Zhang Y, Cao S, Wu Y, Guo W, Yuan W
and Zhang S: miR-411 regulated ITCH expression and promoted cell
proliferation in human hepatocellular carcinoma cells. Biomed
Pharmacother. 70:158–163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao Z, Qin L and Li S: miR-411
contributes the cell proliferation of lung cancer by targeting
FOXO1. Tumour Biol. 37:5551–5560. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang X, Zhang M, Cheng J, Lv Z, Wang F
and Cai Z: MiR-411 functions as a tumor suppressor in renal cell
cancer. Int J Biol Markers. 32:e454–e460. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao J, Liu D, Li J, Song Q and Wang Q:
Effect of STK17A on the sensitivity of ovarian cancer cells to
paclitaxel and carboplatin. Oncol Lett. 12:1107–1112. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mao P, Hever-Jardine MP, Rahme GJ, Yang E,
Tam J, Kodali A, Biswal B, Fadul CE, Gaur A, Israel MA and Spinella
MJ: Serine/threonine kinase 17A is a novel candidate for
therapeutic targeting in glioblastoma. PLoS One. 8:e818032013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mao P, Hever MP, Niemaszyk LM, Haghkerdar
JM, Yanco EG, Desai D, Beyrouthy MJ, Kerley-Hamilton JS, Freemantle
SJ and Spinella MJ: Serine/threonine kinase 17A is a novel p53
target gene and modulator of cisplatin toxicity and reactive oxygen
species in testicular cancer cells. J Biol Chem. 286:19381–19391.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Prives C and Hall PA: The p53 pathway. J
Pathol. 187:112–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang S, Zhou L, Hong B, van den Heuvel
AP, Prabhu VV, Warfel NA, Kline CL, Dicker DT, Kopelovich L and
El-Deiry WS: Small-molecule NSC59984 restores p53 pathway signaling
and antitumor effects against colorectal cancer via p73 activation
and degradation of mutant p53. Cancer Res. 75:3842–3852. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Muthusami S, Prabakaran DS, An Z, Yu JR
and Park WY: EGCG suppresses Fused Toes Homolog protein through p53
in cervical cancer cells. Mol Biol Rep. 40:5587–5596. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu PP, Chung HW, Liu KC, Wu RS, Yang JS,
Tang NY, Lo C, Hsia TC, Yu CC, Chueh FS, et al: Diallyl sulfide
induces cell cycle arrest and apoptosis in HeLa human cervical
cancer cells through the p53, caspase- and mitochondria-dependent
pathways. Int J Oncol. 38:1605–1613. 2011.PubMed/NCBI
|
|
26
|
Au Yeung CL, Tsang TY, Yau PL and Kwok TT:
Human papillomavirus type 16 E6 induces cervical cancer cell
migration through the p53/microRNA-23b/urokinase-type plasminogen
activator pathway. Oncogene. 30:2401–2410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Waggoner SE: Cervical cancer. Lancet.
361:2217–2225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Meva J, Chaudhary RK, Bhaduri D, Bhatia M,
Hatti S and Ba R: Lacunae in International Federation of Gynecology
and Obstetrics (FIGO) classification for cervical carcinoma:
Observational study using TNM classification as comparator. Int J
Gynecol Cancer. 23:1071–1077. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thomas A, Mahantshetty U, Kannan S,
Deodhar K, Shrivastava SK, Kumar-Sinha C and Mulherkar R:
Expression profiling of cervical cancers in Indian women at
different stages to identify gene signatures during progression of
the disease. Cancer Med. 2:836–848. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao S, Yao D, Chen J and Ding N:
Circulating miRNA-20a and miRNA-203 for screening lymph node
metastasis in early stage cervical cancer. Genet Test Mol
Biomarkers. 17:631–636. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo L, Yuan J, Xie N, Wu H, Chen W, Song S
and Wang X: miRNA-411 acts as a potential tumor suppressor miRNA
via the downregulation of specificity protein 1 in breast cancer.
Mol Med Rep. 14:2975–2982. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang G, Zhang Y, Zhao X, Meng C, Ma L and
Kong Y: MicroRNA-411 inhibited matrix metalloproteinase 13
expression in human chondrocytes. Am J Transl Res. 7:2000–2006.
2015.PubMed/NCBI
|
|
35
|
Ozeki M, Salah A, Aini W, Tamaki K, Haga H
and Miyagawa-Hayashino A: Abnormal localization of STK17A in Bile
Canaliculi in liver allografts: An early sign of chronic rejection.
PLoS One. 10:e01363812015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Park Y, Kim W, Lee JM, Park J, Cho JK,
Pang K, Lee J, Kim D, Park SW, Yang KM and Kim SJ: Cytoplasmic
DRAK1 overexpressed in head and neck cancers inhibits TGF-β1 tumor
suppressor activity by binding to Smad3 to interrupt its complex
formation with Smad4. Oncogene. 34:5037–5045. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu Y, Li L, Liu Y, Geng P, Li G, Yang Y
and Song H: RECK inhibits cervical cancer cell migration and
invasion by promoting p53 signaling pathway. J Cell Biochem.
119:3058–3066. 2017. View Article : Google Scholar
|
|
38
|
Shi C and Zhang Z: MicroRNA-362 is
downregulated in cervical cancer and inhibits cell proliferation,
migration and invasion by directly targeting SIX1. Oncol Rep.
37:501–509. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lever J, Gakkhar S, Gottlieb M, Rashnavadi
T, Lin S, Siu C, Smith M, Jones M, Krzywinski M, Jones SJM and Wren
J: A collaborative filtering based approach to biomedical knowledge
discovery. Bioinformatics. 34:652–659. 2017. View Article : Google Scholar
|
|
40
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nadal E, Zhong J, Lin J, Reddy RM, Ramnath
N, Orringer MB, Chang AC, Beer DG and Chen G: A MicroRNA cluster at
14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res.
20:3107–3117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kim YW, Kim EY, Jeon D, Liu JL, Kim HS,
Choi JW and Ahn WS: Differential microRNA expression signatures and
cell type-specific association with Taxol resistance in ovarian
cancer cells. Drug Des Devel Ther. 8:293–314. 2014.PubMed/NCBI
|
|
43
|
Brucker J, Mayer C, Gebauer G, Mallmann P,
Belau AK, Schneeweiss A, Sohn C and Eichbaum M: Non-pegylated
liposomal doxorubicin for patients with recurrent ovarian cancer: A
multicentric phase II trial. Oncol Lett. 12:1211–1215. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tang H, Liu YJ, Liu M and Li X:
Establishment and gene analysis of an oxaliplatin-resistant colon
cancer cell line THC8307/L-OHP. Anticancer Drugs. 18:633–639. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhao J, Xu J and Zhang R: MicroRNA-411
inhibits malignant biological behaviours of colorectal cancer cells
by directly targeting PIK3R3. Oncol Rep. 39:633–642.
2018.PubMed/NCBI
|
|
47
|
Xu N, Yang W, Liu Y, Yan F and Yu Z:
MicroRNA-411 promoted the osteosarcoma progression by suppressing
MTSS1 expression. Environ Sci Pollut Res Int. 25:12064–12071. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cekirge HS, Peynircioglu B and Saatci I:
Endovascular treatment of an ‘anterior cerebral artery’ aneurysm in
a patient with ‘embryonic unfused middle cerebral artery’ anomaly:
A case report. Neuroradiology. 47:690–694. 2005. View Article : Google Scholar : PubMed/NCBI
|
